Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.

Author: BellgroveMark A, ChoSoo-Churl, CumminsTarrant D R, KimBung-Nyun, KimJae-Won

Paper Details 
Original Abstract of the Article :
The purpose of this study was to investigate a possible association between norepinephrine genes and cardiovascular side effects of the Osmotic Controlled-Release Oral Delivery System-methylphenidate (OROS-MPH) in Korean children with attention-deficit/hyperactivity disorder (ADHD). One hundred and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1177/0269881111405356

データ提供:米国国立医学図書館(NLM)

Norepinephrine Transporter and Cardiovascular Side Effects of Methylphenidate

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder often treated with medications like methylphenidate. This research investigates the potential association between genetic variations in norepinephrine-related genes and the cardiovascular side effects of methylphenidate treatment. The study focused on the norepinephrine transporter (SLC6A2) and alpha-2A-adrenergic receptor (ADRA2A) genes, examining the potential link between specific genetic variations and changes in heart rate and blood pressure in children with ADHD receiving methylphenidate treatment.

Genetic Variations and Cardiovascular Response

The researchers found a significant association between specific genetic variations in the SLC6A2 and ADRA2A genes and changes in heart rate and blood pressure after methylphenidate treatment. These findings highlight the importance of considering genetic factors when prescribing methylphenidate to children with ADHD, especially for those with specific genetic variations that may predispose them to increased cardiovascular side effects.

Navigating the Desert of Genetic Variability

This research is a reminder that the desert of human genetics is vast and complex, with individual variations influencing responses to medications. It emphasizes the importance of personalized medicine, tailoring treatment approaches to individual genetic profiles to optimize outcomes and minimize potential side effects. It's like navigating a vast desert, where the terrain changes constantly, requiring careful observation and adaptation to ensure a safe and successful journey.

Dr.Camel's Conclusion

This research is a testament to the power of personalized medicine, recognizing the unique genetic variations that can influence individual responses to treatment. The study emphasizes the importance of considering genetic factors when prescribing medications, particularly those with known cardiovascular side effects. It encourages further research into the genetic basis of drug response, paving the way for more precise and personalized approaches to healthcare.

Date :
  1. Date Completed 2012-08-03
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

21628343

DOI: Digital Object Identifier

10.1177/0269881111405356

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.